JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Molecular and Clinicopathologic Characterization of HER2-overexpressed Squamous Cell Carcinoma of the Cervix

  • 0Department of Pathology, University of Rochester Medical Center, Rochester.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists +

|

October 31, 2024

|

October 31, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

HER2 overexpression in cervical cancer predicts amplification, guiding targeted therapy. Immunohistochemistry reliably identifies HER2 amplification, improving prognosis prediction for this cancer.

Area Of Science

  • Oncology
  • Molecular Pathology
  • Genetics

Background

  • HER2 amplification in cervical cancer correlates with poor prognosis and potential response to HER2 inhibitors.
  • Immunohistochemistry is a common test for HER2 amplification, but lacks standardized scoring for cervical cancers.
  • Investigating HER2 overexpression and amplification is crucial for developing targeted therapies in cervical cancer.

Purpose Of The Study

  • To investigate HER2 overexpression in cervical squamous cell carcinoma.
  • To correlate HER2 overexpression with HER2 amplification using FISH and molecular methods.
  • To establish HER2 immunohistochemistry as a reliable predictive marker for HER2 amplification in cervical cancer.

Main Methods

  • Retrospective review of 72 human papillomavirus-associated cervical cancer cases.
  • HER2 immunohistochemistry staining using 2018 ASCO/CAP breast cancer criteria.
  • FISH and next-generation sequencing for HER2 amplification analysis in cases with equivocal to positive HER2 expression.

Main Results

  • 19 (26.4%) cases showed equivocal HER2 expression; 4 (5.5%) showed positive expression.
  • All 3 evaluable positive cases demonstrated HER2 amplification via FISH.
  • Late clinical stage, high tumor grade, and lymph node metastasis correlated with HER2 overexpression and amplification.

Conclusions

  • HER2 immunohistochemistry is a reliable predictive marker for HER2 amplification in cervical cancer.
  • Standardized HER2 scoring in cervical cancer could improve patient stratification and treatment selection.
  • Further research into co-amplified genes may reveal additional therapeutic targets.

Keywords: